GLP-1s for PCOS (Polycystic Ovary Syndrome) Evidence & Insurance Coverage 2026: Off-Label Use, Trial Data & How to Get Approved

Polycystic ovary syndrome (PCOS) is not an FDA-approved indication for any GLP-1 receptor agonist — Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo are all off-label for it. But the published primary-source evidence base is meaningful: a 4-RCT meta-analysis (Hollanda Morais 2024, PMID 39178623) pooled BMI −2.42 (95% CI −3.10 to −1.74, p<0.00001), waist circumference −5.16 cm, and total testosterone −1.33 nmol/L. The Carmina 2023 semaglutide case series achieved 80% menstrual-cycle restoration. The 2023 International PCOS Guideline endorsed anti-obesity medications including GLP-1s as “may be considered.” And insurance coverage does exist via the comorbidity pathway: Cigna's IP0206 policy explicitly lists “polycystic ovarian syndrome” in its 11-condition GLP-1 weight-management comorbidity list.

Why GLP-1s might help PCOS — the mechanism

PCOS is not just an ovarian disorder — it is a metabolic disorder with insulin resistance as a load-bearing pathophysiologic mechanism. Up to 70% of women with PCOS meet criteria for insulin resistance, and that insulin resistance drives compensatory hyperinsulinemia, ovarian androgen excess, anovulation, and the cardiometabolic risks (hypertension, dyslipidemia, MASLD/MASH, type 2 diabetes) that are over-represented in PCOS populations.

GLP-1 receptor agonists reduce body weight, improve peripheral insulin sensitivity, and slow gastric emptying. In a population whose downstream phenotype is largely insulin-resistance-driven, the same drug class that drives the largest weight reductions ever seen in obesity pharmacology has a plausible mechanism in PCOS — improving insulin sensitivity reduces hyperinsulinemia, which reduces ovarian androgen production, which can restore menstrual regularity and ovulatory cycles. The trial evidence below supports the mechanism in part.

RCT evidence: what trials have shown

Jensterle 2015 — liraglutide vs metformin (PMID 26032655)

The first head-to-head RCT of a GLP-1 against metformin (which had been the conventional first-line PCOS metabolic treatment for two decades) was Jensterle's 2015 pilot in J Ovarian Res. 30 obese PCOS women were randomized across three arms: liraglutide 1.2 mg/day, roflumilast (a PDE4 inhibitor, not relevant here), or metformin 1,000 mg BID for 12 weeks. The verbatim primary findings:

“Subjects treated with LIRA lost on average 3.1 ± 3.5 kg (p = 0.006), on ROF 2.1 ± 2.0 kg (p = 0.002) vs. 0.2 ± 1.83 kg in MET group… LIRA was superior to MET in reducing weight (p = 0.022), BMI (p = 0.020), waist circumference (p = 0.007). LIRA also resulted in decrease in VAT area (p = 0.015).”

Liraglutide outperformed metformin on every body-composition endpoint measured. The trial was small (n=30), short (12 weeks), and used liraglutide 1.2 mg (Saxenda's weight- management dose is 3 mg) — but it established the directional finding that has been replicated since.

Salamun 2018 — liraglutide + metformin pre-IVF (PMID 29703793)

Salamun's 2018 paper in Eur J Endocrinol asked a more direct fertility question: in obese PCOS women who had failed first-line reproductive treatments, does a 12-week course of liraglutide + metformin pre-IVF improve pregnancy rates compared with metformin alone? n=28. Liraglutide was discontinued before conception per the pregnancy contraindication. Findings verbatim:

“The PR per ET was significantly higher in the COMBI (85.7%) compared with the MET (28.6%) group (P = 0.03)” … “The cumulative PR in the time frame of 12 months was 69.2% in the COMBI group compared to 35.7% in the MET group.”

Pre-conception liraglutide + metformin tripled the per- embryo-transfer pregnancy rate vs metformin alone in this difficult-to-treat population. Weight loss was similar between arms (~7 kg both groups, P = 0.246), suggesting the pregnancy-rate advantage was not driven solely by weight loss but by some combination of metabolic optimization and possible direct fertility effects. The clinical takeaway: liraglutide pre-IVF, with mandatory discontinuation before conception, was associated with improved IVF outcomes in obese PCOS-IVF patients who had failed first-line care.

Carmina 2023 — semaglutide for lifestyle-refractory obese PCOS (PMID 37762862)

Carmina & Longo's 2023 J Clin Med paper followed 27 obese PCOS patients on semaglutide 0.5 mg/week for 6 months after they had failed structured lifestyle interventions. Open-label, observational. Findings verbatim:

“Almost 80% of the studied obese PCOS patients obtained at least a 5% decrease in their body weight” … “mean body weight loss was 11.5 kg and mean BMI reduced from 34.4 to 29.4” (at 6 months) … “A total of 80% of responsive patients normalized menstrual cycles.”

80% menstrual-cycle restoration is a clinically meaningful signal — for women whose primary PCOS complaint is oligomenorrhea or amenorrhea, this is a direct quality-of- life endpoint. The weight loss (11.5 kg, 33% reduction in BMI from 34.4 to 29.4) at semaglutide 0.5 mg is in line with what we'd expect for that dose; the menstrual- cycle effect is presumably mediated by the insulin- resistance → androgen excess pathway being interrupted. Open-label observational design caveats apply.

Jensterle 2024 — what happens after semaglutide discontinuation (PMID 38665260)

The same Slovenian PCOS group followed 25 obese PCOS women through 16 weeks of semaglutide 1 mg/week and then 2 years of post-discontinuation follow-up (with continued metformin). At 2 years post-discontinuation:

• Median body weight: 101 kg (baseline) → 92 kg (end of 16-week semaglutide) → 95 kg (2-year post- discontinuation)
• 21 of 25 subjects had lower body weight compared to baseline at 2 years; net weight loss remained statistically significant (p = 0.003)
• Free testosterone: 6.16 → 4.12 nmol/L (p = 0.012) — partial androgen-suppression durability
• About one third of acute weight loss was regained over the 2-year follow-up

This is the most important real-world durability data we have for GLP-1 in PCOS specifically. The pattern is in line with the broader semaglutide weight-regain literature (STEP-1 extension, PMID 35315183): substantial regain occurs after stopping, but most patients remain net-better than baseline at 2 years if they continue metformin and lifestyle interventions. For PCOS, this matters because chronic GLP-1 use during reproductive years collides with the pregnancy-contraindication window (see the fertility section below).

Hollanda Morais 2024 meta-analysis (PMID 39178623)

The strongest pooled-evidence anchor we have is the 2024 meta-analysis in J Diabetes Complications. 4 RCTs, n=176 across intervention + control arms. Verbatim pooled findings:

• Body Mass Index: MD −2.42; 95% CI −3.10 to −1.74; p < 0.00001
• Waist Circumference: MD −5.16 cm; 95% CI −6.11 to −4.21; p < 0.00001
• Total Testosterone: MD −1.33 nmol/L; 95% CI −2.55 to −0.12; p = 0.03
• HOMA-IR: MD −0.30; 95% CI −0.92 to 0.32; p = 0.35 (not significant)
• Total Cholesterol: MD −0.04; 95% CI −0.10 to 0.01; p = 0.15 (not significant)

Honest framing: BMI, waist, and testosterone reductions are confirmed. HOMA-IR and total-cholesterol reductions are not statistically significant in the pooled analysis. The evidence base is small (n=176 across all 4 trials). This is directionally encouraging but not yet at the scale of the STEP / SURMOUNT obesity programs.

The 2023 International PCOS Guideline (Teede et al)

The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (Teede et al, J Clin Endocrinol Metab 2023, PMID 37580314) was developed by the Monash Centre for Health Research and Implementation with the European Society of Human Reproduction and Embryology (ESHRE), the American Society for Reproductive Medicine (ASRM), and the Endocrine Society. It is the global anchor guideline for PCOS care.

On anti-obesity pharmacotherapy including GLP-1s, the guideline endorsed pharmacologic adjuncts to lifestyle intervention for PCOS-associated obesity, with the supporting systematic review (Goldberg et al 2024, PMID 38355887) reporting verbatim that:

“Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included… liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes… Published data examining the effects of anti-obesity agents in women with PCOS are very limited. The role of these agents in PCOS should be a high priority for future research.”

The honest framing the guideline takes is what we should also take: the evidence supports use, but it is limited and warrants caution. Liraglutide and semaglutide outperform placebo for anthropometric outcomes; the broader cardiometabolic and reproductive endpoints have weaker pooled evidence; tirzepatide-specific PCOS RCT outcome data had not yet published as of mid-2026 (two trials are recruiting on ClinicalTrials.gov, NCT06325449 and NCT07326111).

Insurance: how PCOS qualifies for GLP-1 weight-management coverage

PCOS is not an FDA-approved GLP-1 indication. Plans cannot cover GLP-1s “for PCOS” per se. They can cover GLP-1s for chronic weight management in patients with BMI ≥ 27 + a weight-related comorbidity, where polycystic ovarian syndrome is one of the listed qualifying comorbidities under several major insurer policies.

Cigna IP0206 — the canonical 2026 Cigna weight-loss GLP-1 coverage policy (covers Wegovy, Zepbound, Foundayo, Saxenda) — explicitly lists polycystic ovarian syndrome as one of 11 qualifying weight-related comorbid conditions for the BMI ≥ 27 pathway (alongside hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, chronic obstructive pulmonary disease, MASLD/NAFLD, and coronary artery disease). For the full verbatim policy language and the exact PA-form criteria, see our Cigna GLP-1 prior-authorization guide.

Aetna uses a similar comorbidity framework in its 4774-C Wegovy and 6947-C / 6981-A Zepbound bulletins. For the verbatim Aetna criteria and the formulary-swap context (CVS Caremark July 2025 Wegovy-preferred change), see the Aetna GLP-1 PA guide.

Practical PA-success patterns for PCOS patients:

• Document the BMI and the comorbidity together. The PA form needs both: BMI ≥ 27 (ideally ≥ 30 for stronger documentation) AND a confirmed PCOS diagnosis (ICD-10 E28.2). PCOS diagnosis without elevated BMI does not unlock weight-management GLP-1 coverage on these policies.
• Confirm the PCOS diagnosis with current criteria (Rotterdam 2003 / 2023 International Guideline). Two of three: oligo-/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound — with exclusion of mimickers (CAH, Cushing, androgen-secreting tumors, thyroid disease, hyperprolactinemia).
• Bundle metabolic comorbidities if present. Many PCOS patients also meet criteria for prediabetes, dyslipidemia, or hypertension. PA approval is more reliable when multiple comorbidities are documented.
• Anticipate the metformin step-therapy requirement. Some plans require a documented trial of metformin before approving a GLP-1 for PCOS- adjacent weight management. Metformin is well-evidenced and inexpensive; the step is usually accepted by the patient.
• Use the Letter of Medical Necessity pattern documented in the appeal playbook. See our insurance appeal playbook for the LOMN structure that has worked for PCOS denials.

Fertility, pregnancy contraindication, and the 8-week washout

Every GLP-1 receptor agonist is contraindicated in pregnancy. The Wegovy / Ozempic / Saxenda labels advise discontinuation at least 2 months before a planned pregnancy because of the long terminal half-life (~1 week for semaglutide, ~13 hours for liraglutide). The Zepbound / Mounjaro label has similar contraindication language. Foundayo's label requires its own pre- conception washout based on orforglipron pharmacokinetics.

For PCOS patients trying to conceive, this creates a real clinical timing problem:

• Pre-conception phase: GLP-1 may improve metabolic profile, restore ovulation, and (per Salamun 2018) improve IVF success rates.
• Discontinuation phase (8+ weeks before conception): patient must stop the GLP-1. Metformin can typically be continued through pregnancy per ACOG and ESHRE guidance.
• Pregnancy: GLP-1 contraindicated. Weight regain may begin; metabolic gains may erode.
• Postpartum: GLP-1 can be resumed once the patient is no longer breastfeeding (the labels also contraindicate use during breastfeeding) — though some clinicians and recent label updates allow restart with informed consent.

Patients on GLP-1 for PCOS-driven weight management who are not actively trying to conceive should use reliable contraception. The Mounjaro / Zepbound label specifically recommends a non-oral contraceptive method (or adding a barrier method to oral contraceptives) for 4 weeks after starting and after each dose escalation, because tirzepatide slows gastric emptying and reduces oral-contraceptive bioavailability. See our Mounjaro/Zepbound + birth control evidence guide for the verbatim §5 warning.

Metformin vs GLP-1 in PCOS — when does each make sense?

Metformin has been first-line for PCOS metabolic care for 25+ years. It is inexpensive, well-tolerated, available generic, and pregnancy-compatible in most cases. Its weight- loss effect is modest (~2-4 kg). Its insulin-sensitizing effect is strong.

GLP-1 RAs produce 5-15× more weight loss than metformin in PCOS studies, restore ovulation more reliably (Carmina 80%), and improve testosterone more directly. They are more expensive, harder to access (PA-gated), and contraindicated in pregnancy.

The decision logic that aligns with the published evidence:

• Metformin first for most PCOS patients — especially those with BMI < 27, those who are pregnancy- adjacent, those who can't access GLP-1 coverage, or those whose primary issue is glycemic / insulin-resistance rather than BMI.
• GLP-1 added or substituted when BMI ≥ 27, metabolic benefit is incomplete on metformin alone, weight-related comorbidity is documented, and PA coverage is achievable.
• Combination (metformin + GLP-1) is consistent with the Slovenian Salamun protocol; metformin can be continued during the GLP-1 pre-conception washout and through pregnancy in most cases.
• Anti-androgen + spironolactone + combined oral contraceptive (the conventional PCOS dermatologic / gynecologic regimen) addresses hyperandrogenism / hirsutism / acne directly — GLP-1s improve this only via weight + insulin-sensitivity pathways and should not replace anti-androgen therapy when that's the primary complaint.

Bottom line

GLP-1s are off-label for PCOS but the evidence base is meaningful: 4 RCTs in the Hollanda Morais 2024 meta-analysis confirm BMI −2.42, waist −5.16 cm, and total testosterone −1.33 nmol/L (PMID 39178623); Carmina's 2023 series achieved 80% menstrual-cycle restoration on semaglutide (PMID 37762862); Salamun's 2018 IVF study tripled per-ET pregnancy rates pre-conception (PMID 29703793); the 2023 International Guideline endorses the class as “may be considered.” Insurance access is real on the comorbidity pathway — Cigna IP0206 explicitly lists PCOS as a qualifying weight-related condition. Tirzepatide-specific PCOS RCT outcomes had not yet published as of mid-2026 (two trials recruiting). Pregnancy contraindication still requires GLP-1 discontinuation at least 8 weeks before conception, which collides with PCOS fertility goals — patients need to plan the timing carefully with their reproductive endocrinologist.

Related research

• What birth control causes weight loss? An evidence review — relevant when PCOS patients are deciding between a combined oral contraceptive (for hyperandrogenism / cycle / acne) and a GLP-1 (for weight). The honest evidence answer: hormonal contraceptives do not reliably cause weight loss, so the contraceptive choice and the weight-management choice are separate decisions.
• GLP-1 pregnancy, PCOS, fertility & women's health (broader scope)
• GLP-1, menstrual cycle, period changes & hormones
• Mounjaro & Zepbound + birth control bioavailability
• Cigna GLP-1 prior-authorization guide
• Aetna GLP-1 prior-authorization guide
• Insurance appeal playbook (LOMN + IRO + cash-pay bridge)
• GLP-1 medications pillar (every approved + investigational agent)
• FDA-approved weight-loss medications hub